logo
logo

Affinivax Announces $120 Million Series B Financing to Advance Pipeline of Novel MAPS Vaccines and Immunotherapies

Apr 23, 2020•over 5 years ago

Amount Raised

$120 Million

Round Type

series b

Cambridge

Description

Affinivax, Inc. ("Affinivax"), a clinical stage biotechnology company with its novel MAPS technology platform for vaccines and immunotherapies, today announced the completion of a $120 million Series B financing round, led by Viking Global Investors with participation from Bain Capital Life Sciences and Ziff Capital Partners. This represents the first financing round to be completed since the company’s founding in June 2014, when Affinivax received an initial seed and Series A equity investment from the Bill & Melinda Gates Foundation. The company has leveraged the initial investment, non-dilutive grant funding, and a partnership with Astellas Pharma to advance its novel Multiple Antigen Presentation System (“MAPS”) vaccine technology into clinical trials

Company Information

Company

Affinivax

Location

Cambridge, Maryland, United States

About

Affinivax is advancing a next generation technology platform to enable the development of vaccines and immunotherapies. Backed by investments from Viking Global Investors, Bain Capital Life Sciences, Ziff Capital Partners, and the Bill & Melinda Gates Foundation, Affinivax is focused on the most challenging bacterial infections, both improving upon existing vaccines and providing vaccines for which there are no prevention strategies available today. The company’s proprietary technology platform, called MAPS, enables the high affinity binding of protective polysaccharides and proteins in a single vaccine or immunotherapy to uniquely induce a broad and protective B and T cell immune response. The company’s lead pneumococcal vaccine, in a partnership with Astellas Pharma, includes 24 pneumococcal serotypes, more than any other vaccine on the market or in clinical testing today. This vaccine has been demonstrated to be safe and highly immunogenic in healthy adults and is currently in Phase 2 clinical trials. In addition to targeting Streptococcus pneumoniae, the company is advancing a pipeline of MAPS vaccines targeting the most common hospital-associated infections (HAIs), and is also extending the utility of MAPS to a range of other potential applications, including vaccines and immunotherapies targeting viral diseases and cancer. For more information, visit www.affinivax.com.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech